KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

J Clin Oncol · 2025-Jan-20 · PMID 39250535

Panel D质量警告待 EXE 对齐验证

PFS

FIG 2. PFS by treatment and key subgroups. Data cutoff: March 29, 2023. (A) Kaplan-Meier curves for PFS in the full analysis set, (B) HRs of PFS in key subgroups, (C) Kaplan-Meier curves for PFS in patients with nonsquamous histology, and (D) Kaplan-Meier curves for PFS in patients with squamous histology. PFS was assessed by blinded independent central review. Tick marks in the Kaplan-Meier curves represent censored data. HRs and CIs in the forest plot were calculated on the basis of the patient data in the electronic case report forms for the histology and actionable genomic alteration subgroups. a Regardless of histology. Dato-DXd, datopotamab deruxtecan; HR, hazard ratio; PFS, progression-free survival.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.58
质量通过否
预期曲线2
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T18:11:51+00:00